Availability of FDA Statement Added to the Docket for Public Meeting Related to Cosmetic Products Containing Talc

Riepilogo

The Food and Drug Administration (FDA or we) is announcing the availability of a statement added to the docket for the public meeting entitled "Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc" to address information provided in connection with the public meeting. FDA held the public meeting on February 4, 2020, to discuss and obtain scientific data and information on topics related to cosmetic products with talc as an ingredient, specifically, testing methodologies, terminology, and criteria that could be applied to characterize and measure asbestos and other potentially harmful elongate mineral particles (EMPs) that may be present as contaminants in such products. The meeting included presentations by members of an interagency working group (the Interagency Working Group on Asbestos in Consumer Products or IWGACP).